Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | ||
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rydapt | Midostaurin | Systemic Mastocytosis | Do not reimburse | Complete | ||
| Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nubeqa | Darolutamide | non-metastatic castration resistant prostate cancer (nmCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete |
Last Updated : May 12, 2024